EXAGEN INC. (XGN): Price and Financial Metrics

EXAGEN INC. (XGN): $16.16

-0.25 (-1.52%)

POWR Rating

Component Grades













XGN Stock Summary

  • Exagen Inc's stock had its IPO on September 19, 2019, making it an older stock than just 1.65% of US equities in our set.
  • Of note is the ratio of Exagen Inc's sales and general administrative expense to its total operating expenses; 76% of US stocks have a lower such ratio.
  • In terms of twelve month growth in earnings before interest and taxes, Exagen Inc is reporting a growth rate of 66.64%; that's higher than 83.37% of US stocks.
  • Stocks that are quantitatively similar to XGN, based on their financial statements, market capitalization, and price volatility, are SREV, BCPC, EVER, BOXL, and ADMS.
  • Visit XGN's SEC page to see the company's official filings. To visit the company's web site, go to avisetest.com.

XGN Stock Price Chart Interactive Chart >

Price chart for XGN

XGN Price/Volume Stats

Current price $16.16 52-week high $24.67
Prev. close $16.41 52-week low $10.29
Day low $16.12 Volume 14,995
Day high $17.40 Avg. volume 62,652
50-day MA $18.50 Dividend yield N/A
200-day MA $15.04 Market Cap 204.75M

EXAGEN INC. (XGN) Company Bio

Exagen, Inc. is a commercial-stage diagnostics company. It engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company operates under the Avise brand.

XGN Latest News Stream

Event/Time News Detail
Loading, please wait...

XGN Latest Social Stream

Loading social stream, please wait...

View Full XGN Social Stream

Latest XGN News From Around the Web

Below are the latest news stories about Exagen Inc that investors may wish to consider to help them evaluate XGN as an investment opportunity.

Are Institutions Heavily Invested In Exagen Inc.'s (NASDAQ:XGN) Shares?

The big shareholder groups in Exagen Inc. ( NASDAQ:XGN ) have power over the company. Insiders often own a large chunk...

Yahoo | April 16, 2021

Wasatch Advisors increased stake in Exagen Inc.


Investing.com | April 9, 2021

Exagen Inc. Announces Study on the Long-Term Effects of COVID-19 Infection in the Development of Autoimmune Diseases

SAN DIEGO, March 29, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases. Emory is widely acknowledged as a leading research institution in the study of various autoimmune diseases, including lupus. The longitudinal study will further evaluate the emergence of biomarkers that are known indicators for the development of lupus, rheumatoid arthritis and other autoimmune diseases. This effort will assess the emergence of these biomarkers in mild/moderate COVID patients, among several critical patient groups, includi...

Yahoo | March 29, 2021

Exagen Inc. Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, March 25, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced that it has closed its previously announced underwritten public offering of 4,255,000 shares of its common stock, including 555,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $16.25 per share. The gross proceeds to Exagen from the offering, before deducting the underwriting discounts and commissions and other offering expenses, were approximately $69.1 million. Exagen intends to use the net proceeds from the proposed offering for the development of Multi-omics capabilities, including build out of its clinical laboratory, advancement of its product pipeline, incl...

Yahoo | March 25, 2021

Exagen raises $60M via equity offering

Exagen (XGN) has priced its public offering of 3.7M common shares at $16.25/share, for expected gross proceeds of $60.1M.Underwriters' over-allotment is an additional 555K shares. Net proceeds will be used for build out of clinical laboratory, advancement of its product pipeline, for working capital and other general corporate purposes.Closing date...

Seeking Alpha | March 23, 2021

Read More 'XGN' Stories Here

XGN Price Returns

1-mo -19.20%
3-mo -1.52%
6-mo 11.99%
1-year 6.67%
3-year N/A
5-year N/A
YTD 22.42%
2020 -48.03%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.9839 seconds.